Wed, Apr 23, 2014, 1:44 PM EDT - U.S. Markets close in 2 hrs 16 mins

Recent

% | $
Quotes you view appear here for quick access.

Amarin Corporation plc Message Board

  • larrystone13 larrystone13 Mar 1, 2013 7:33 PM Flag

    Motley Fool " I DON'T EXCEPT A CO. TO GIVE GUIDANCE AFTER ONE MONTHS OF SALES. ( link )

    Motley Fool
    By Brian Orelli | More Articles | Save For Later
    March 1, 2013

    Unfortunately, management was light on the details last night beyond qualitative comments such as CEO Joseph Zakrzewski saying, "we're pleased to-date with the progress that our sales representatives are making out in the field."

    I don't expect a company to give full-year guidance after a drug has been on the market for a month. If management did give guidance, it would likely be completely useless since any smart management team would be insanely conservative with their guidance. Regeneron Pharmaceuticals (NASDAQ: REGN ) raised guidance for its macular degeneration drug, Eylea, four times last year. That's not guidance; that's guesses. And bad ones at that. Eylea sales were five times higher than initial estimates.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
AMRN
1.620.00(-0.31%)1:43 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.